Keyword: Johnson & Johnson
Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.
With the failure of its lead program in pancreatic cancer, Halozyme is cutting drug development to focus solely on its drug delivery technology.
Most top R&D executives from across biopharma are earning around $7 million a year.
2. Paul Stoffels, Johnson & Johnson
The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D.
J&J and Ethicon reached a deal with the attorneys general of 41 states and DC, agreeing to pay nearly $117 million.
The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,
As the industry’s digital transformation is fueled by tools such as AI and machine learning, certain R&D projects promise to have outsized impacts.
So-called digital surgery combines robotic instrumentation with computer-aided visualization and decisionmaking, supplementing them with a continuum of outcome data tracking patients before, during and after the procedure.
As the biopharma industry’s digital transformation continues apace, with the rapid acceptance of tools such as artificial intelligence and machine learning, certain projects promise to yield impacts on a much wider scale.
